Skip to main content
. 2023 Jun 21;24(13):10455. doi: 10.3390/ijms241310455

Table 2.

Medicinal products containing cannabinoids approved by the FDA and/or EMA.

Drug Indication
Epidiolex
(oral solution containing
100 mg/mL of cannabidiol)

  • Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older

  • Adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older
Marinol
(capsules containing
2.5, 5, or 10 mg of dronabinol)

  • Anorexia associated with weight loss in patients with AIDS

  • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
Syndros
(oral solution containing
5 mg/mL of dronabinol)
Sativex
(oromucosal spray containing 2.7 mg/mL of Δ9-tetrahydrocannabinol and 2.5 mg/mL of
cannabidiol from Cannabis sativa L.)

  • Treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy
Cesamet
(capsules containing
1 mg of nabilone)

  • Treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments